Results 111 to 120 of about 16,303 (230)
Transfusion, EarlyView.Abstract Background Clinical guidelines recommend transfusing ABO‐identical platelets where possible. However, the short shelf life of platelets (5–7 days) and stock availability mean ABO‐nonidentical platelet transfusions are sometimes unavoidable. Minor ABO‐incompatible platelet transfusions carry a risk of hemolysis due to donor anti‐A/B antibodies,
Melanie J. Robbins +5 more
wiley +1 more source
Inhibition of thrombin generation by group 1 anti-fVIII MAbs.
, 2012 Thrombin generation curves are shown for fVIII deficient plasma (negative control), fVIII deficient plasma with 1 U/ml of fVIII (positive control) and 1 U/ml of fVIII in the presence of 5 µg/ml of specified group 1 MAb.
Bagirath Gangadharan (124016) +3 more
core +1 more source
Decoding full-length factor VIII through the structural and functional lens of its B domain
Blood Vessels, Thrombosis & Hemostasis: The factor VIII (FVIII) B domain, a large and heavily glycosylated region, is crucial for FVIII secretion, although its structural and functional roles remain incompletely understood. Although the B domain is dispensable for cofactor activity, previous
Samhitha Urs Ramaraje Urs +11 more
doaj +1 more source
New Insights Into Pathogenesis, Diagnostics, and Therapeutic Options for Canine Angiostrongylosis
Journal of Veterinary Emergency and Critical Care, EarlyView.ABSTRACT Objective To provide a comprehensive overview of Angiostrongylus vasorum infection in dogs, with a particular emphasis on recent developments in the understanding of disease pathophysiology and an update on developments in diagnostic and therapeutic options.
Iris Elgueta +3 more
wiley +1 more source
Transplanted human cells produce FVIII.
, 2013 The graph represents ELISA measurements of human FVIII in the plasma of untransplanted uPA-NOG mice (n = 5) and mice transplanted with human fetal liver cells (n = 22).
Ashley I. Beyer (426501) +5 more
core +1 more source
Clinical and Translational Discovery, Volume 6, Issue 5, October 2026.The inhibitor kinetics type cannot be used by itself to determine auto‐ versus allo‐anti‐FVIII antibody type. To characterise inhibitor kinetics in inherited haemophilia A (HA) and acquired haemophilia A (AHA) patients in our centre, results show that inhibitors for both HA alloantibodies and AHA autoantibodies may exhibit either type I or type II ...
Cuicui Qiao +10 more
wiley +1 more source
International Journal of Laboratory Hematology, Volume 48, Issue 5, Page 951-960, October 2026.ABSTRACT Borderline prolongation of routine clotting assays—particularly the activated partial thromboplastin time (aPTT)—is a common interpretative challenge in laboratory hematology. These reproducible but mildly prolonged results often lie just beyond the upper reference limit and can trigger unnecessary follow‐up, delays, or misinterpretation ...
Nikolaos Androulakis +3 more
wiley +1 more source
Immunofluorescence images of FVIII expression by EC.
, 2013 a: Sequential confocal fluorescence microscopy images in primary human EC. a and b: Representative HPMEC and HPAEC control images using To-Pro-3 nuclear counterstain (first panel, monochrome), murine control IgG1 (second panel monochrome) and merged ...
Kay Elderfield (367173) +9 more
core +1 more source
Interaction between VWF and FVIII in treating VWD
, 2015 In patients with von Willebrand disease (VWD), the absence of von Willebrand factor (VWF) antigen leads to the premature loss of endogenous circulating secreted factor VIII (FVIII), thereby resulting in the dual defect in haemostasis.
Erik Berntorp +3 more
core +2 more sources
Rescue of the endogenous FVIII expression in hemophilia A mice using CRISPR-Cas9 mRNA LNPs
Molecular Therapy: Nucleic AcidsGene editing provides a promising alternative approach that may achieve long-term FVIII expression for hemophilia A (HemA) treatment. In this study, we investigated in vivo correction of a mutant factor VIII (FVIII) gene in HemA mice.
Chun-Yu Chen +3 more
doaj +1 more source